BTX - Lineage Cell Therapeutics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.9199
-0.0701 (-7.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9900
Open0.9100
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range0.9000 - 0.9600
52 Week Range0.6600 - 2.6100
Volume694,268
Avg. Volume457,312
Market Cap137.657M
Beta (3Y Monthly)N/A
PE Ratio (TTM)3.97
EPS (TTM)N/A
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of BTX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 BioTime Inc Earnings Call

  • Business Wire

    BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen ® Conducted Sale of 2.25 Million Shares of OncoCyte Corporation Initiated Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System ...

  • BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should You Be Excited About BioTime, Inc.'s (NYSEMKT:BTX) 35% Return On Equity?
    Simply Wall St.

    Should You Be Excited About BioTime, Inc.'s (NYSEMKT:BTX) 35% Return On Equity?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Is Forbuild SA’s (WSE:BTX) 16% ROCE Any Good?
    Simply Wall St.

    Is Forbuild SA’s (WSE:BTX) 16% ROCE Any Good?

    Today we'll look at Forbuild SA (WSE:BTX) and reflect on its potential as an investment. In particular, we'll consider...

  • Thomson Reuters StreetEvents

    Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 BioTime Inc Earnings Call

  • Business Wire

    BioTime Announces Appointment of General Counsel

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary. “We’re extremely fortunate to have Chase join us and bring his extensive public company experience as well as a strong track record to the role of general counsel,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Don't Sell Forbuild SA (WSE:BTX) Before You Read This
    Simply Wall St.

    Don't Sell Forbuild SA (WSE:BTX) Before You Read This

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • BioTime (BTX) Q1 2019 Earnings Call Transcript
    Motley Fool

    BioTime (BTX) Q1 2019 Earnings Call Transcript

    BTX earnings call for the period ending March 31, 2019.

  • Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
    Zacks

    Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

    Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

  • Business Wire

    BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Company’s retinal pigment epithelium transplant therapy currently in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. To date, the IIA has provided annual grants totaling approximately $15 million for the development of the OpRegen program.

  • BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
    Zacks

    BioTime (BTX) Tops Q1 Earnings and Revenue Estimates

    BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    BioTime: 1Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had profit of 30 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire

    BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. BioTime, Inc. , a clinical-stage biotechnology company developing cellular therapies for unmet medical ...

  • Business Wire

    BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) for United States Patent Application No. 15/156,316 for a method of reducing spinal cord injury (SCI)-induced parenchymal cavitation in patients that have suffered an acute spinal cord injury. The claimed method involves injecting oligodendrocyte progenitor cells (OPCs) derived from human pluripotent stem cells into the SCI site and covers both human embryonic and induced pluripotent stem cell-derived OPCs. “We believe OPC1 acts via several distinct mechanisms to aid the recovery of SCI patients, one of which is the prevention or reduction of cavitation, and we are pleased at having received an allowance on this important patent, which we believe further enhances our OPC1 cell therapy program,” stated Brian M. Culley, Chief Executive Officer of BioTime.

  • Business Wire

    BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, May 9th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2019 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.

  • Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know

    BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA), will be presented today at the 2019 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) in Vancouver, BC, Canada. Data from the study demonstrate that treatment with OpRegen continues to be well tolerated and in some patients, signs of structural improvement in the treated areas of the retina have been observed.

  • Benzinga

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

    Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV )'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong ...

  • Business Wire

    BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference

    BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”. Dr. Wirth’s presentation is entitled “Top-line 12-month Results from the SCiStar Study - A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (OPC1) in Patients with Subacute Cervical Spinal Cord Injury”. “We believe the primary goals of the SCiStar Study, which were to observe the safety of OPC1 in cervical spinal cord injury patients as well as other important metrics including related to the optimal timing of OPC1 injection, tolerability of the immunosuppression regimen, engraftment of OPC1 cells, and rates of motor recovery observed among different study subpopulations, have all been successfully achieved,” stated Dr. Wirth.

  • Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%?
    Simply Wall St.

    Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%?

    It is a pleasure to report that the BioTime, Inc. (NYSEMKT:BTX) is up 37% in the last quarter. But that is small recompense for the exasperating returns over three years. Tragically, the share price declined 58% in that ti...

  • Business Wire

    BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

    BioTime, Inc. , a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration with geographic atrophy, will be presented at the 2019 Association ...